General Information of Drug Therapeutic Target (DTT) (ID: TTQO71U)

DTT Name Hemoglobin (HB)
Synonyms Hemoglobin subunit alpha; Hemoglobin alpha chain; HBA1; Alpha-globin
Gene Name HBA2
DTT Type
Successful target
[1]
BioChemical Class
Pore-forming globin
UniProt ID
HBA_HUMAN
TTD ID
T49493
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MVLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTKTYFPHFDLSHGSAQVKGHG
KKVADALTNAVAHVDDMPNALSALSDLHAHKLRVDPVNFKLLSHCLLVTLAAHLPAEFTP
AVHASLDKFLASVSTVLTSKYR
Function Involved in oxygen transport from the lung to the various peripheral tissues.
KEGG Pathway
African trypanosomiasis (hsa05143 )
Malaria (hsa05144 )
Reactome Pathway
Erythrocytes take up oxygen and release carbon dioxide (R-HSA-1247673 )
Scavenging of heme from plasma (R-HSA-2168880 )
Erythrocytes take up carbon dioxide and release oxygen (R-HSA-1237044 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
3 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Iron DMAP8MV Anemia of prematurity Approved [1]
Iron Dextran DM5OY70 Iron-deficiency anemia 3A00 Approved [1]
Voxelotor DMCS6M5 Sickle-cell disorder 3A51 Approved [2]
------------------------------------------------------------------------------------
9 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Efaproxyn DMX7BM4 Lung cancer 2C25.0 Phase 3 [3]
PolyHeme DMV8EXG Blood forming organ disorder JB64.1 Phase 3 [4]
GBT021601 DMD3C21 Sickle-cell disorder 3A51 Phase 2/3 [5]
Hemoglobin raffimer DMMTL7V Anemia 3A00-3A9Z Phase 2/3 [6]
5-hydroxymethyl-2-furfural DMPFVJB Anemia 3A00-3A9Z Phase 2 [7]
FBS-0701 DMR3952 Iron overload disease 5C64.10 Phase 2 [8]
HQK-1001 DM7QUN0 Beta thalassemia 3A50.2 Phase 2 [9]
CTX110 DMJ7LP0 Non-hodgkin lymphoma 2B33.5 Phase 1/2 [10]
OXY-111A DMTH75R Cardiovascular disease BA00-BE2Z Phase 1/2 [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Clinical Trial Drug(s)
9 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hemoximer DMGYKDN Hypotension BA20-BA21 Discontinued in Phase 3 [12]
VX-366 DMH4U87 Constitutional neutropenia 4B00.0 Discontinued in Phase 2 [13]
HRC-302 DMH32LM Chronic myelogenous leukaemia 2A20.0 Discontinued in Phase 1 [14]
AN-10 DM50HB8 Alopecia ED70 Terminated [15]
Diaspirin crosslinked hemoglobin DM61BWZ Cerebrovascular ischaemia 8B1Z Terminated [16]
HRC-101 DMEZ5P2 Blood transfusion QB98 Terminated [17]
HRC-102 DMJACXN Reperfusion injury ND56.Z Terminated [18]
HRC-201 DM5A3GX Liver cancer 2C12 Terminated [18]
RHb1.1 DM7CY0T Anemia 3A00-3A9Z Terminated [19]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Discontinued Drug(s)
7 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
1,3,5-BENZENETRICARBOXYLIC ACID DMNCWXZ Discovery agent N.A. Investigative [20]
2,6-DICARBOXYNAPHTHALENE DM8JFNU Discovery agent N.A. Investigative [20]
2-[(2-methoxy-5-methylphenoxy)methyl]pyridine DMXA1LK Discovery agent N.A. Investigative [20]
4-Carboxycinnamic Acid DMBIQV3 Discovery agent N.A. Investigative [20]
4-[(5-methoxy-2-methylphenoxy)methyl]pyridine DMNMC9O Discovery agent N.A. Investigative [20]
Heme DMGC287 Discovery agent N.A. Investigative [20]
SEBACIC ACID DM3VOPQ Discovery agent N.A. Investigative [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Investigative Drug(s)

References

1 Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9.
4 Blood substitutes- the polyheme trials. Mcgill J Med. 2008 January; 11(1): 59-65.
5 GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. Br J Haematol. 2023 Jul;202(1):173-183.
6 Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness. Can J Anaesth. 2005 Apr;52(4):369-73.
7 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb;128(4):552-61.
8 A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 1;15(23):7144-52.
9 A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in beta-thalassaemia intermedia. Br J Haematol. 2014 Feb;164(3):456-8.
10 Clinical pipeline report, company report or official report of CRISPR Therapeutics.
11 Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators. Br J Haematol. 1998 Sep;102(5):1165-71.
12 Effect of NaBH4 Concentration and Reaction Time on Physical Properties of Glutaraldehyde-Polymerized Hemoglobin. Biotechnology Progress. 05/2004; 20(3):946-52.
13 A combination of hydroxyurea and isobutyramide to induce fetal hemoglobin in transgenic mice is more hematotoxic than the individual agents. Blood Cells Mol Dis. 1999 Jun-Aug;25(3-4):255-69.
14 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014790)
15 Genes for Development, Cell Growth and Infectious Diseases, Gabriel Gachelin, 1995. Page(215).
16 Diaspirin cross-linked hemoglobin infusion did not influence base deficit and lactic acid levels in two clinical trials of traumatic hemorrhagic shock patient resuscitation. J Trauma. 2010 May;68(5):1158-71.
17 The novel hemoglobin-based oxygen carrier HRC 101 improves survival in murine sickle cell disease. Anesthesiology. 2007 Aug;107(2):281-7.
18 WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
19 Effects of recombinant-hemoglobin solutions rHb2.0 and rHb1.1 on blood pressure, intestinal blood flow, and gut oxygenation in a rat model of hemorrhagic shock. J Lab Clin Med. 2005 Jan;145(1):21-32.
20 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.